
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate is a clinical-stage biopharmaceutical company that is focused on developing and commercializing products for the treatment of ADHD and anxiety. Their initial focus is on the development of two proprietary first-line stimulant medications for ADHD in both children and adults. The company has a large market potential with millions of potential patients and strong growth in the ADHD medication market. Current valuation is attractive with significant upside potential, but there are risks to attaining their price target. A potential approval in mid or late 2026 could be a strong positive catalyst for the stock.
Bears say
Cingulate is facing potential challenges with gaining FDA approval for their first-line stimulant medications, CTx-1301 and CTx-1302, due to receiving a CRL that requires additional CMC information. However, their utilization of PTR technology shows promise for a once-daily, multi-dose tablet, and with no safety or efficacy concerns, the company has potential for FDA approval. While the recent Q4 results showed a net loss and no guidance, the company's recent stock raise provides enough cash to sustain operations until mid-2027.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares